This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Inter-Assay Growth Hormone and IGF-I Variability

This study has been withdrawn prior to enrollment.
Information provided by:
Cedars-Sinai Medical Center Identifier:
First received: January 11, 2008
Last updated: October 3, 2008
Last verified: September 2008
The purpose of this study is to demonstrate the degree of variability in commercially available assays for Growth Hormone measurement in the context of clinical decision making for Growth Hormone (GH) deficiency and Acromegaly and to determine variability among IGF-I inter-assay samples obtained at the time of Growth-Hormone Releasing Hormone Arginine Testing and Oral Glucose Tolerance Testing.

Acromegaly Growth Hormone Deficiency

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inter-Assay Growth Hormone and IGF-I Variability

Resource links provided by NLM:

Further study details as provided by Cedars-Sinai Medical Center:

Biospecimen Retention:   Samples With DNA
  1. Group I Growth Hormone Deficiency (GHD): subjects with pituitary disease undergoing testing for GH deficiency: GHRH-ARG Test, collect total of 84 cc whole blood.
  2. Group II Acromegaly: subjects with suspicion for (or diagnosis of) acromegaly undergoing OGTT Test, collect total of 48 cc whole blood.
  3. Group III Normal Controls: subjects without evidence of pituitary dysfunction undergoing OGTT Test, collect total of 136 cc whole blood.

Estimated Enrollment: 171
Study Start Date: November 2007
Estimated Study Completion Date: January 2011
Detailed Description:

This research will explore the variability of GH and IGF-1 measurements by commercially available tests. The hypothesis is that the variability in GH and IGF-1 measurement will be sizable enough that different conclusions would be drawn in patient case decision making in the diagnosis and management of GH deficiency and acromegaly.

In order to correctly diagnose disorders of growth hormone secretion, either deficiency or excess, it is necessary to have the accurate measurement of GH (growth hormone) serum and Insulin-like growth factor (IGF-1).

For this study, subjects will be asked to give the Investigators additional blood during either an OGTT (a test for acromegaly) or a growth hormone stimulation test (GHRH-arginine stimulation). Ordinarily, blood would be measured at the beginning and end of the OGTT, and for the GHRH-arginine it would be measured one half hour before the test and then every half hour for 2 hours.

For this study, subjects will provide us with additional blood at the times when blood is drawn for the clinically-indicated tests. No additional needle sticks will be necessary and taking the additional blood will not interfere with the clinical test.

The test we will be doing with the additional blood will be identical to the tests we ordinarily do, but will be done by a different lab. We are testing to see if these results would be the same as our usual lab.

The study population will include 1) subjects with pituitary disease undergoing testing for GH deficiency (GHRH arginine stimulation test), 2) subjects with suspicion of acromegaly undergoing the oral glucose tolerance test (oGTT), and 3) normal controls undergoing both the GHRH Arginine test and the oGTT. Patients from all groups will have their blood drawn for the measurement of IGF-1. The serum from each test will be aliquoted and sent to the designated labs.

For subject groups 1 and 2, this study poses no more than minimal risk, as it involves procedures that do not go beyond clinical care. For healthy controls, we know that participants will be asked to undergo testing that would not normally be required, and therefore feel that the study poses more than minimal risk.

For the primary endpoint research samples will be compared to samples sent to the usual clinical lab, and diagnoses made based on research samples will be compared to clinical samples.

For secondary endpoints, each result from a commercially available assay will be correlated to another corresponding method of analysis of the same hormone from the same time point by using the Bland-Altman analysis wherein the difference between two methods is compared to the mean of the two methods. Each sample will be compared to the sample used for clinical evaluation.

Information from the medical records will be obtained and correlated with the lab test results.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
tertiary referral center

Inclusion Criteria:

  1. Male or Female age 18+
  2. Clinical indication for testing GH response to secretagogue testing to evaluate for GHD OR clinical indication for testing for GH response to oral glucose load (75grams of glucose) to evaluate for Acromegaly either for diagnosis OR normal volunteer for control group.

    • Normal volunteers will be screened for evidence of pituitary endocrine dysfunction prior to Oral Glucose Tolerance Testing (OGTT) and Growth Hormone Releasing Hormone - Arginine Testing (GHRH-ARG).
  3. Able to provide informed consent

Exclusion Criteria:

  1. Subjects taking GH
  2. Pregnant or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00638287

Sponsors and Collaborators
Cedars-Sinai Medical Center
Principal Investigator: John Carmichael, MD Cedars-Sinai Medical Center
  More Information

Responsible Party: Inter-Assay Growth Hormone and IGF-I Variability, CSMC Identifier: NCT00638287     History of Changes
Other Study ID Numbers: 10638
Study First Received: January 11, 2008
Last Updated: October 3, 2008

Keywords provided by Cedars-Sinai Medical Center:
Subjects with pituitary disease undergoing testing for GH
Subjects with suspicion for (or diagnosis of) acromegaly
undergoing OGTT testing
Normal controls without evidence of pituitary dysfunction

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 25, 2017